An adverse drug reaction (ADR) is any unintended, harmful response to a drug administered at a dose used in humans for prophylaxis, diagnosis, or therapy. ADRs represent a major source of patient harm globally, contributing to hospital admissions, prolonged inpatient stays, and preventable deaths. A systematic classification framework provides the conceptual structure for anticipating, recognizing, and managing adverse effects across all drug classes.
The most widely used classification system categorizes ADRs into types A through F, each reflecting a distinct mechanism and clinical pattern. Type A reactions (augmented) are dose-dependent extensions of the drug's primary pharmacological action; they are predictable, common, and generally manageable by dose reduction. The excessive bradycardia seen with beta-blockers and the bleeding associated with anticoagulants are Type A reactions. Because they result from the drug's intended mechanism, Type A reactions are the most amenable to anticipation and prevention. They account for the large majority of all ADRs -- approximately 80% in most estimates. Type B reactions (bizarre) are idiosyncratic, dose-independent, unpredictable, and not related to the drug's known pharmacological actions. They are typically immunologically mediated (drug hypersensitivity) or result from pharmacogenomic variation (e.g., succinylcholine-induced prolonged paralysis in patients with pseudocholinesterase deficiency, or halothane hepatitis). Type B reactions are rarer than Type A but are often more serious and have higher mortality.1
Types C Through F. Type C reactions (chronic) develop only with prolonged drug use and reflect cumulative effects on tissue or organ function; examples include hypothalamic-pituitary-adrenal (HPA) axis suppression with long-term corticosteroid use, analgesic nephropathy with chronic non-steroidal anti-inflammatory drug (NSAID) use, and tardive dyskinesia (TD) from years of antipsychotic exposure. Type D reactions (delayed) emerge long after drug exposure, sometimes years later; carcinogenesis from alkylating agents and teratogenesis from thalidomide are prototypical examples. Type E reactions (end-of-use) occur on drug withdrawal: rebound hypertension on clonidine discontinuation, seizures on abrupt antiepileptic withdrawal, and adrenal insufficiency after corticosteroid cessation are all Type E. Type F reactions (failure) represent unexpected therapeutic failure, most commonly caused by drug interactions that reduce drug concentrations -- for example, contraceptive failure due to enzyme induction by rifampin or certain anticonvulsants reducing circulating hormone levels.12
Drug Hypersensitivity Reactions. Drug hypersensitivity represents a subset of Type B reactions mediated by immunological mechanisms and is classified by the Gell-Coombs system into four types. Type I reactions are IgE (immunoglobulin E)-mediated immediate hypersensitivity, occurring within minutes to an hour of drug exposure and manifesting as urticaria, angioedema, bronchospasm, or anaphylaxis; penicillin-induced anaphylaxis is the classic example. Type II reactions are IgG (immunoglobulin G)-mediated cytotoxic reactions in which drug-hapten complexes on cell surfaces are targeted by antibody and complement; methyldopa-induced hemolytic anemia and penicillin-induced thrombocytopenia are examples. Type III reactions are immune complex-mediated (serum sickness-like reactions), presenting with fever, arthralgia, urticaria, and lymphadenopathy 1-3 weeks after drug initiation; historically caused by heterologous antisera, now more commonly by monoclonal antibodies and some antibiotics. Type IV reactions are delayed-type hypersensitivity mediated by T lymphocytes, occurring 48-72 hours after exposure; contact dermatitis from topical agents and some drug-induced liver injury patterns are Type IV.23
Drug-induced anaphylaxis: acute onset (minutes), bronchospasm, urticaria, angioedema, hypotension, cardiovascular collapse. First-line treatment: epinephrine (adrenaline) 0.3-0.5 mg IM into the anterolateral thigh (0.3-0.5 mL of 1 mg/mL solution); not subcutaneous. Repeat every 5-15 minutes as needed. Adjuncts: IV fluids, diphenhydramine, H2 antagonists, corticosteroids (delayed effect only). Document allergy clearly and provide medic alert information. Cross-reactivity between penicillins and cephalosporins is approximately 1-2%, less than historically estimated.
Pharmacokinetic drug interactions alter the plasma concentration of one drug by affecting its absorption, distribution, metabolism, or elimination when a second drug is co-administered. Unlike pharmacodynamic interactions, the object drug (the drug whose concentration is altered) may not share any mechanism of action with the precipitant drug (the drug causing the interaction). The magnitude of pharmacokinetic interactions is highly variable among patients, and clinically significant interactions produce plasma concentrations that are either supertherapeutic (toxicity) or subtherapeutic (treatment failure).
Absorption Interactions. Drug-drug interactions at the level of absorption can reduce or increase oral bioavailability by several mechanisms. Chelation and adsorption: antacids containing aluminum (Al) or magnesium (Mg) hydroxide, calcium carbonate, and iron salts form insoluble chelates with tetracyclines and fluoroquinolones, dramatically reducing their absorption -- patients must be counseled to separate these medications by at least 2 hours. Colestyramine and other bile acid sequestrants adsorb many drugs in the gastrointestinal (GI) tract, reducing their absorption. Gastric pH changes: drugs that reduce gastric acidity (proton pump inhibitors (PPIs), H2 (histamine receptor 2) receptor antagonists) impair the dissolution and absorption of drugs that require an acidic environment for ionization-dependent dissolution, including itraconazole capsules (a clinical problem avoided by using the oral solution formulation). Intestinal motility changes: drugs that accelerate gastric emptying (metoclopramide) may increase the rate of absorption of poorly soluble drugs, while opioids that slow GI transit may delay peak concentrations.4
Metabolism Interactions -- CYP Inhibition and Induction. Cytochrome P450 (CYP) enzyme interactions are the largest and most clinically important class of pharmacokinetic drug interactions, discussed extensively in the pharmacokinetics module. At the practical level, the clinician must know the major CYP (cytochrome P450) substrates, inhibitors, and inducers across the key isoforms: CYP3A4 (cytochrome P450 3A4) substrates include cyclosporine, tacrolimus, midazolam, statins, and many antiretrovirals; potent inhibitors include azole antifungals, clarithromycin, erythromycin, and ritonavir; potent inducers include rifampin, carbamazepine, phenytoin, phenobarbital, and St. John's wort. For CYP2C9 (cytochrome P450 2C9) substrates (warfarin S-enantiomer, phenytoin), potent inhibitors include fluconazole and amiodarone, with clinically significant increases in INR (international normalized ratio) and phenytoin toxicity. For CYP2C19 (cytochrome P450 2C19) substrates (clopidogrel, PPIs), co-administration of omeprazole or esomeprazole reduces clopidogrel activation, potentially diminishing antiplatelet efficacy; pantoprazole has a weaker CYP2C19 inhibitory effect and is preferred. The time course of interactions differs: competitive inhibition is immediate, while mechanism-based inhibition and induction develop over days to weeks.4
Distribution and Elimination Interactions. Protein binding displacement interactions were historically considered important, but their clinical significance is now recognized as limited for most drugs because the free drug made available by displacement is rapidly cleared, so steady-state free drug concentrations change only transiently. The interaction retains clinical significance for drugs with very high protein binding, very small volume of distribution (Vd), and narrow therapeutic windows -- warfarin being the most cited example, though the displacement component of warfarin-drug interactions is generally less important than the concurrent CYP2C9 inhibition. Renal elimination interactions occur when two drugs compete for the same active tubular secretion transporters: classic examples include probenecid blocking tubular secretion of methotrexate, penicillins, and cephalosporins, substantially increasing their plasma concentrations and toxicity risk. Probenecid is exploited therapeutically to prolong penicillin half-life, but its co-administration with methotrexate in patients with renal impairment can cause life-threatening methotrexate toxicity.4
Rifampin + cyclosporine/tacrolimus: expect 50-80% reduction in immunosuppressant exposure -- risk of transplant rejection; avoid or intensively monitor with dose adjustment. Warfarin + fluconazole or amiodarone: significant INR elevation within days; reduce warfarin dose and check INR within 3-5 days. Clopidogrel + omeprazole: reduced active metabolite; switch to pantoprazole. St. John's wort + any CYP3A4 substrate: enzyme induction reduces substrate concentrations -- particularly dangerous with antiretrovirals, calcineurin inhibitors, and combined oral contraceptives. Methotrexate + NSAIDs: NSAIDs reduce renal methotrexate clearance via prostaglandin-mediated renal vasoconstriction; potentially fatal in high-dose regimens.
Pharmacodynamic drug interactions occur when two or more drugs affect the same physiological process or receptor target, altering the net pharmacological response without changing plasma concentrations of either drug. These interactions are mechanistically predictable from knowledge of each drug's mechanism of action and are often deliberately exploited therapeutically; they can also produce dangerous toxicity when combinations are not anticipated.
Additive and Synergistic Interactions. An additive pharmacodynamic interaction occurs when two drugs producing the same effect are combined and the combined effect equals the sum of their individual effects. Synergism describes a combined effect that exceeds the sum of individual effects. Both types are widely exploited in clinical medicine: combination antihypertensive therapy uses drugs acting on different components of blood pressure regulation (e.g., an angiotensin-converting enzyme (ACE) inhibitor reducing renin-angiotensin-aldosterone system (RAAS) activity combined with a calcium channel blocker (CCB) reducing vascular tone) to achieve superior blood pressure lowering than either drug alone, while also reducing the dose-dependent side effects of each individual agent. Combination antibiotic therapy can be synergistic: beta-lactam antibiotics plus aminoglycosides produce synergistic killing of certain Gram-negative pathogens by disrupting cell wall synthesis (beta-lactam) and thereby enhancing aminoglycoside uptake across the compromised bacterial membrane. Co-trimoxazole, the fixed-dose combination of trimethoprim and sulfamethoxazole, exploits sequential blockade of the same folate biosynthesis pathway -- trimethoprim inhibiting dihydrofolate reductase (DHFR) and sulfamethoxazole inhibiting dihydropteroate synthase (DHPS) -- producing synergistic antibacterial and antiparasitic activity at lower individual doses than either drug alone.6
Antagonistic Interactions. Pharmacodynamic antagonism occurs when the combined effect of two drugs is less than the sum of their individual effects. Competitive pharmacodynamic antagonism is the basis of several important antidote and reversal strategies: naloxone reverses opioid-induced respiratory depression by competitively displacing opioids from mu-opioid receptors; flumazenil reverses benzodiazepine-induced sedation by competitive antagonism at the GABA-A (gamma-aminobutyric acid type A) receptor benzodiazepine binding site; neostigmine (an acetylcholinesterase inhibitor) reverses non-depolarizing neuromuscular blockade by increasing acetylcholine concentrations at the neuromuscular junction, competing with the blocking agent for nicotinic acetylcholine receptor occupancy. In each case, the reversal agent must be administered in quantities sufficient to displace the agonist from its binding site, and the duration of action of the reversal agent must be considered relative to the duration of the drug being reversed. Naloxone has a shorter duration of action than most opioids, requiring repeated dosing or infusion in severe opioid overdose to prevent re-narcotization after the naloxone effect wanes.6
Dangerous Additive Toxicity Combinations. Some of the most clinically hazardous pharmacodynamic interactions arise from additive toxicity rather than additive or synergistic therapeutic effects. Central nervous system (CNS) depression is additively increased by any combination of opioids, benzodiazepines, non-benzodiazepine hypnotics (z-drugs), alcohol, antihistamines, antipsychotics, and gabapentinoids, with respiratory depression and death as the extreme outcome. Additive QTc prolongation from drugs that block cardiac potassium channels (the rapid delayed rectifier potassium current (IKr)) represents one of the most dangerous interaction categories in clinical practice: combining two or more QTc-prolonging drugs -- including many antipsychotics, methadone, fluoroquinolone antibiotics, azole antifungals, and some antiemetics -- can precipitate torsades de pointes ventricular tachycardia, a potentially fatal arrhythmia. Additive bleeding risk from antiplatelet agents combined with anticoagulants substantially increases the risk of serious hemorrhage above that of either agent alone, requiring careful risk-benefit assessment and, when necessary, co-prescription of gastric protection.78
Drugs with significant QTc-prolonging potential: antipsychotics (haloperidol, quetiapine, ziprasidone), methadone, sotalol, amiodarone, fluoroquinolones (moxifloxacin, ciprofloxacin), azole antifungals, some macrolides (azithromycin, erythromycin), ondansetron (high doses), citalopram. Combining two or more drugs from this list multiplies torsades de pointes risk. Check baseline QTc before initiating; monitor QTc during treatment; correct electrolyte abnormalities (hypokalemia, hypomagnesemia potentiate IKr block). Resources: CredibleMeds/AZCERT QTDrug database provides risk stratification.
Beyond drug-drug interactions, clinicians must anticipate the impact of diet and pre-existing disease states on drug safety and efficacy. Drug-food interactions span a spectrum from minor absorption effects to life-threatening pharmacodynamic combinations. Drug-disease interactions arise when a drug's pharmacological mechanism is harmful in the context of specific pathophysiological states, and recognizing these contraindications is a fundamental element of prescribing competence.
Grapefruit Juice Interactions. Grapefruit juice contains furanocoumarins (principally bergamottin and 6,7-dihydroxybergamottin) that irreversibly inhibit intestinal CYP3A4 (cytochrome P450 3A4) and, to a lesser extent, P-glycoprotein (P-gp). Because the inhibition is mechanism-based and irreversible, the effect persists for 24-72 hours after a single glass of grapefruit juice, and drinking grapefruit juice regularly keeps intestinal CYP3A4 chronically suppressed. Drugs with high first-pass CYP3A4 metabolism and narrow therapeutic windows are most significantly affected, with plasma concentrations increasing two-fold to five-fold or more: simvastatin and lovastatin (but not pravastatin or rosuvastatin) show substantial concentration increases, raising myopathy and rhabdomyolysis risk; felodipine, amlodipine, and other dihydropyridine CCBs show markedly increased plasma concentrations, causing excessive hypotension; cyclosporine and tacrolimus concentrations increase substantially, risking nephrotoxicity and other calcineurin inhibitor toxicity. Patients on affected medications should be advised to avoid grapefruit and grapefruit juice entirely, or switch to alternative drugs not metabolized by intestinal CYP3A4.58
Tyramine and Monoamine Oxidase Inhibitors. Monoamine oxidase inhibitors (MAOIs) -- including phenelzine, tranylcypromine, and selegiline at high doses -- irreversibly inhibit both MAO-A (monoamine oxidase A) and MAO-B (monoamine oxidase B) isoforms, the enzymes responsible for catabolizing dietary tyramine in the intestinal wall and liver. Under normal circumstances, tyramine absorbed from tyramine-rich foods (aged cheeses, cured meats, fermented foods, certain wines) is efficiently inactivated by MAO (monoamine oxidase) before reaching the systemic circulation. When MAO is inhibited, dietary tyramine passes into the systemic circulation and triggers massive norepinephrine release from sympathetic nerve terminals (the tyramine pressor response), producing a hypertensive crisis that can cause intracranial hemorrhage or myocardial infarction. Patients on MAOIs must follow a strict low-tyramine diet, avoiding aged cheeses, cured or smoked meats, pickled or fermented foods, tap beer, red wine, and certain other foods. This dietary restriction is a significant practical burden and is one reason MAOIs have been largely replaced by other antidepressants in routine practice.68
Clinically Important Drug-Disease Interactions. Drug-disease contraindications arise when a drug's pharmacological mechanism causes harm in the context of a specific pathological state. Beta-blockers are contraindicated in decompensated heart failure (they depress myocardial contractility when cardiac output is severely impaired), in high-degree atrioventricular (AV) block (they further depress conduction), and in severe reactive airways disease (beta-2 blockade produces bronchoconstriction). NSAIDs are contraindicated in chronic kidney disease (CKD) because prostaglandin inhibition causes afferent arteriolar constriction, reducing renal perfusion and worsening renal function; they are also contraindicated in active peptic ulcer disease and in the third trimester of pregnancy (premature closure of the ductus arteriosus). Metformin, the first-line oral agent for type 2 diabetes, is contraindicated in significant renal impairment (estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² requires cessation) because impaired renal clearance of metformin increases the risk of life-threatening lactic acidosis. Fluoroquinolones are relatively contraindicated in patients with QTc prolongation, hypokalemia, or hypomagnesemia and should be used cautiously with other QTc-prolonging drugs for the reasons described in Section 3.78
ADR types: A (augmented, dose-dependent, ~80% of all ADRs), B (bizarre, idiosyncratic), C (chronic), D (delayed), E (end-of-use withdrawal), F (failure). Drug hypersensitivity: Type I (IgE, anaphylaxis), II (cytotoxic), III (immune complex), IV (delayed T-cell). Pharmacokinetic interactions: chelation (tetracyclines + antacids), CYP inhibition (azoles, clarithromycin, ritonavir), CYP induction (rifampin, carbamazepine), renal transport competition (probenecid + methotrexate). Pharmacodynamic: additive CNS depression, additive QTc prolongation (torsades de pointes risk), synergistic antibiotics (co-trimoxazole). Grapefruit: irreversible CYP3A4 inhibition, 24-72h duration. MAOIs + tyramine: hypertensive crisis. Key contraindications: NSAIDs in CKD, beta-blockers in decompensated HF, metformin in eGFR <30.
Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2019. ISBN 9780702074486.
ISBN 9780702074486Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
doi:10.1016/S0140-6736(00)02799-9Johansson SGO, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization. J Allergy Clin Immunol. 2004;113(5):832-836.
doi:10.1016/j.jaci.2003.12.591Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641-651.
doi:10.1002/pds.1351Bailey DG, Dresser G, Arnold JM. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013;185(4):309-316.
doi:10.1503/cmaj.120951Katzung BG, Trevor AJ, eds. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill; 2021. ISBN 9781260452310.
ISBN 9781260452310Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11(1):83-94.
doi:10.1517/14740338.2012.631910Waller DG, Sampson AP. Medical Pharmacology and Therapeutics. 5th ed. Edinburgh: Elsevier; 2018. ISBN 9780702071676.
ISBN 9780702071676